Stock 4123 CENTER LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Center Laboratories, Inc.

Equities

4123

TW0004123005

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
42.95 TWD -0.92% Intraday chart for Center Laboratories, Inc. +2.26% -3.05%
Apr. 22 Center Laboratories, Inc. cancelled the transaction announced on June 20, 2023 CI
Mar. 19 Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 23,380 24,362 31,736 30,555 28,132 30,630
Enterprise Value (EV) 1 24,763 28,753 34,577 31,068 29,252 32,827
P/E ratio 4.18 x -84.5 x 8.42 x 17.3 x 278 x -29.5 x
Yield 2.21% 2.5% 2.16% 4.02% 2.1% 3.39%
Capitalization / Revenue 1.08 x 16.9 x 44.3 x 61.1 x 36.6 x 22 x
EV / Revenue 1.14 x 20 x 48.2 x 62.1 x 38.1 x 23.5 x
EV / EBITDA 11.3 x 2,126 x -82 x -141 x 92.5 x 152 x
EV / FCF 5.33 x -37.5 x 6,826 x -5.65 x 4.54 x -13.9 x
FCF Yield 18.8% -2.67% 0.01% -17.7% 22% -7.22%
Price to Book 1.8 x 1.87 x 1.76 x 1.61 x 1.46 x 1.54 x
Nbr of stocks (in thousands) 573,729 589,200 634,365 636,165 653,737 691,421
Reference price 2 40.75 41.35 50.03 48.03 43.03 44.30
Announcement Date 4/1/19 3/31/20 3/31/21 3/30/22 3/28/23 3/19/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 21,648 1,438 717 500.1 767.7 1,394
EBITDA 1 2,201 13.53 -421.5 -220.8 316.1 216
EBIT 1 1,278 -89.43 -471.8 -254.2 284.1 78.56
Operating Margin 5.9% -6.22% -65.8% -50.82% 37.01% 5.64%
Earnings before Tax (EBT) 1 9,782 100.8 5,997 2,596 -588.9 -1,114
Net income 1 6,084 -286.4 3,786 1,816 102.2 -995.4
Net margin 28.1% -19.92% 528.07% 363.16% 13.31% -71.41%
EPS 2 9.749 -0.4893 5.938 2.779 0.1547 -1.500
Free Cash Flow 1 4,644 -766.8 5.066 -5,495 6,445 -2,369
FCF margin 21.45% -53.34% 0.71% -1,098.83% 839.46% -169.93%
FCF Conversion (EBITDA) 210.98% - - - 2,038.91% -
FCF Conversion (Net income) 76.33% - 0.13% - 6,305.03% -
Dividend per Share 2 0.8989 1.034 1.080 1.931 0.9022 1.500
Announcement Date 4/1/19 3/31/20 3/31/21 3/30/22 3/28/23 3/19/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 1,383 4,390 2,841 513 1,120 2,197
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.6284 x 324.5 x -6.739 x -2.321 x 3.544 x 10.17 x
Free Cash Flow 1 4,644 -767 5.07 -5,495 6,445 -2,369
ROE (net income / shareholders' equity) 48.8% -1.32% 27.1% 10.3% -2.85% -5.31%
ROA (Net income/ Total Assets) 2.72% -0.26% -1.16% -0.54% 0.64% 0.19%
Assets 1 223,464 110,793 -325,745 -333,366 16,014 -529,198
Book Value Per Share 2 22.60 22.10 28.30 29.80 29.40 28.80
Cash Flow per Share 2 2.550 1.110 1.460 0.4200 1.220 2.480
Capex 1 1,781 620 71.7 7.55 7.28 169
Capex / Sales 8.23% 43.13% 10% 1.51% 0.95% 12.15%
Announcement Date 4/1/19 3/31/20 3/31/21 3/30/22 3/28/23 3/19/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CENTER LABORATORIES, INC. Stock Center Laboratories, Inc.
-3.05% 903M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4123 Stock
  4. Financials Center Laboratories, Inc.